N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide - CAS:453562-69-1 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
英文名称:	N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
别名:	莫替沙尼 Motesanib
CAS No:	453562-69-1	分子式:	C₂₂H₂₃N₅O	分子量:	373.46
CAS No:	453562-69-1
分子式:	C₂₂H₂₃N₅O
分子量:	373.46

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF)

M11524 N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide ≥98% (psaitong)

相关产品

AZD2932
CAS No：883986-34-3
(S)-2-(4-(4-(4-(5-(1-氨基-1-(4-氟苯基)乙基)嘧啶-2-基)哌嗪-1-基)吡咯并[2,1-f][1,2,4]三嗪-6-基)-1H-吡唑-1-基)乙醇
CAS No：2505078-08-8
Bezuclastinib
CAS No：1616385-51-3
Vimseltinib
CAS No：1628606-05-2
托西尼布
CAS No：356068-94-5
N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
CAS No：453562-69-1

包装规格：

10mg 50mg 250mg in glass bottle

溶解性：

溶于DMSO（≥100mg/mL）

产品描述：

基本信息

产品编号：M11524
产品名称：N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide
CAS:	453562-69-1	储存条件	粉末	-20℃	四年

分子式：	C22H23N5O		溶于液体	-80℃	六个月
分子量	373.46			-20℃	一个月
化学名：
Solubility (25°C)	体外	DMSO	18.2mg/mL (48.73mM)
		Ethanol	8mg/mL (21.42mM)
		Water	Insoluble
	体内（现配现用）
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.6777mL	13.3887mL	26.7773mL
5mM	0.5355mL	2.6777mL	5.3555mL
10mM	0.2678mL	1.3389mL	2.6777mL

生物活性

产品描述	一种有效的 VEGFR1/2/3 的 ATP 竞争性抑制剂，IC50 值2nM/3nM/6 nM，与对 Kit 的选择性相似，是 PDGFR 和 Ret 的 10 倍多。
靶点/IC50	VEGFR1 2nM (IC50)	VEGFR2 3nM (IC50)	VEGFR3 6nM (IC50)
体外研究	Motesanib has broad activity against the human VEGFR family, and displays > 1000 selectivity against EGFR, Src, and p38 kinase. Motesanib significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000nM. Motesanib also potently inhibits PDGF-induced proliferation and SCF-induced c-kit phosphorylation with IC50 of 207nM and 37nM, respectively, but not effective against the EGF-induced EGFR phosphorylation and cell viability of A431 cells[1]. Althouth displaying little antiproliferative activity on cell growth of HUVECs alone, Motesanib treatment significantly sensitizes the cells to fractionated radiation.
体内研究	Motesanib (100mg/kg) significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1mg/kg and 4.9mg/kg, respectively. Motesanib induces a dosedependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells.Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma.(HNSCC) xenograft models. Motesanib treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen.

推荐实验方法(仅供参考)

激酶实验：

Optimal enzyme, ATP, and substrate (gastrin peptide) concentrations are established for each enzyme using homogeneous time-resolved fluorescence (HTRF) assays. Motesanib is tested in a 10-point dose-response curve for each enzyme using an ATP concentration of two-thirds Km for each. Most assays consist of enzyme mixed with kinase reaction buffer [20mM TrisHCl (pH 7.5),10mM MgCl2, 5mM MnCl2, 100mM NaCl, 1.5mM EGTA]. A final concentration of 1mM DTT, 0.2mM NaVO4, and 20μg/mL BSA is added before each assay. For all assays, 5.75mg/mL streptavidin-allophycocyanin and 0.1125nM Eu-PT66 are added immediately before the HTRF reaction. Plates are incubated for 30 minutes at room temperature and read on a Discovery instrument. IC50 values are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equation.

细胞实验:

Cells are preincubated for 2 hours with different concentrations of Motesanib, and exposed with 50 ng/mL VEGF or 20 ng/mL bFGF for an additional 72 hours. Cells are washed twice with DPBS, and plates are frozen at -70°C for 24 hours. Proliferation is assessed by the addition of CyQuant dye, and plates are read on a Victor 1420 workstation. IC50 data are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equatio.

动物实验:

A431 cells are cultured in DMEM (low glucose) with 10% FBS and penicillin/streptomycin/glutamine. Cells are harvested by trypsinization, washed, and adjusted to a concentration of 5×107/mL in serum-free medium. Animals are challenged s.c.with 1×107 cells in 0.2mL over the left flank. Approximately 10 days thereafter, mice are randomized based on initial tumor.volume measurements and treated with either vehicle (Ora-Plus) or Motesanib. Tumor volumes and body weights arerecorded twice weekly and/or on the day of sacrifice. Tumor volume is measured with a Pro-Max electronic digital caliper and calculated using the formula length (mm)×width (mm)×height (mm) and expressed in mm3. Data are expressed as mean±SE.Repeated measures ANOVA followed by Scheffe post hoc testing for multiple comparisons is used to evaluate the statistical significance of observed differences.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献